EMA Recommends Extension of Indications for Dostarlimab By Ogkologos - January 23, 2025 664 0 Facebook Twitter Google+ Pinterest WhatsApp Change concerns the first-line treatment of patients with endometrial cancer Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Changes in Metabolism Help Melanomas Spread January 21, 2020 Immunotherapy Drug Cemiplimab Approved for Advanced Squamous Cell Skin Cancer October 19, 2018 ESMO 2020: New Treatments for Advanced Kidney Cancer, Prostate Cancer, and... October 20, 2020 AI and remote monitoring are shaping a new patient journey in... August 26, 2025 Load more HOT NEWS 3 Questions Cancer Caregivers Can Ask Themselves to Help Prevent Burnout Listening to Patient Narratives T-DM1 is Active and Well Tolerated in Patients with HER2-positive Metastatic... Grabbing the Perfect Gift
